Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alx Oncology Holdings Inc (NQ: ALXO )

1.625 +0.145 (+9.80%)
Streaming Delayed Price Updated: 2:34 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alx Oncology Holdings Inc

< Previous 1 2 Next >
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
ALX Oncology Realigns Executive Leadership Team
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces September Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
From ALX Oncology
Via GlobeNewswire
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Scott Garland to its Board of Directors
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Upcoming Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept
Expects to extend cash runway to mid-2025 
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From ALX Oncology
Via GlobeNewswire
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
From Zymeworks Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.